AstraZeneca tired of life? Leaves London and reorganizes global R&D
This article was originally published in Scrip
AstraZeneca's new CEO Pascal Soriot has wasted little time in putting his stamp on the troubled company since joining six months ago. Today saw the firm announcing sweeping changes to its R&D operations around the globe. This comes just three days before the unveiling of Mr Soriot's strategy review conclusions at an investor day in New York.